MedTrace Logo

Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

NCT05833724 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-03-11

No results posted yet for this study

Summary

This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.

Conditions

  • Relapsed or Refractory Peripheral T-cell Lymphoma

Interventions

DRUG

Chidamide

Subjects will receive a single dose of 30 mg chidamide. Twice a week.

Sponsors & Collaborators

  • Great Novel Therapeutics Biotech & Medicals Corporation

    lead INDUSTRY

Principal Investigators

  • Chia-Nan Chen, Ph.D. · Great Novel Therapeutics Biotech & Medicals Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-18
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05833724 on ClinicalTrials.gov